Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exscientia Ltd ADR (NQ: EXAI )

6.950 +0.660 (+10.49%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 23, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 785,702
Open 6.470
Bid (Size) 6.450 (23)
Ask (Size) 7.000 (1)
Prev. Close 6.290
Today's Range 6.322 - 7.110
52wk Range 4.090 - 16.53
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Earnings Scheduled For March 23, 2023
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter. 
Via Benzinga
Exscientia Business and Financial Update for the Full Year 2022
From Exscientia
Via Business Wire

Performance

YTD
+23.89%
+23.89%
1 Month
+0.58%
+0.58%
3 Month
+48.50%
+48.50%
6 Month
-12.91%
-12.91%
1 Year
-54.28%
-54.28%

More News

Read More
A Preview Of Exscientia's Earnings
Via Benzinga
Barclays Maintains Overweight Rating for Exscientia: Here's What You Need To Know
Via Benzinga
Evogene Offers An Excellent Risk/Reward Ratio
Via Talk Markets
Exscientia to Report Full Year 2022 Financial Results on March 23, 2023
From Exscientia plc
Via Business Wire
Exscientia to Present Data Highlighting Pipeline and Precision Medicine Platform at AACR
From Exscientia plc
Via Business Wire
Exscientia Announces Expansion of its Precision Oncology Pipeline
From Exscientia plc
Via Business Wire
Exscientia Announces Collaboration with Charité to Advance Development of Precision Medicine Platform
From Exscientia plc
Via Business Wire
Exscientia to Present at Upcoming Investor Conferences in March
From Exscientia plc
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
BP, Hertz Global, Take-Two Interactive Software And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318
From Exscientia plc
Via Business Wire
US Stocks Open Lower; Dow Drops 125 Points
Via Benzinga
Exscientia Presents Novel Immuno-Oncology Biomarker for EXS-21546 at the ESMO I-O Annual Congress
From Exscientia plc
Via Business Wire
Exscientia Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours
From Exscientia plc
Via Business Wire
Exscientia Business and Financial Update for the Third Quarter 2022
From Exscientia plc
Via Business Wire
Earnings Scheduled For November 15, 2022
Via Benzinga
Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments
From Exscientia plc
Via Business Wire
Exscientia to Report Third Quarter 2022 Financial Results on November 15, 2022
From Exscientia plc
Via Business Wire
Exscientia Expands Biologics Design Capability with Automated Laboratory
From Exscientia plc
Via Business Wire
Exscientia to Present at Upcoming Investor Conferences in November
From Exscientia
Via Business Wire
Exscientia Wins Prix Galien USA 2022 Digital Health Solution Award
From Exscientia plc
Via Business Wire
Exscientia Presents Novel Patient Stratification and Biomarker Data for GTAEXS-617 at the 34th EORTC-NCI-AACR Annual Symposium
From Exscientia plc
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.